Therapeutic Nanobodies Targeting Cell Plasma Membrane Transport Proteins: A High-Risk/High-Gain Endeavor
| Autor: | Nick Devoogdt, Timo W.M. De Groof, Serge Muyldermans, Raf Van Campenhout, Mathieu Vinken |
|---|---|
| Přispěvatelé: | Pharmaceutical and Pharmacological Sciences, Faculty of Medicine and Pharmacy, Experimental in vitro toxicology and dermato-cosmetology, Cellular and Molecular Immunology, Vriendenkring VUB, Liver Connexin and Pannexin Research Group, Connexin Signalling Research Group, Supporting clinical sciences, Medical Imaging, Translational Imaging Research Alliance |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Drug High-gain antenna media_common.quotation_subject Cell lcsh:QR1-502 Review Biochemistry Models Biological lcsh:Microbiology drug target 03 medical and health sciences 0302 clinical medicine Extracellular medicine Humans cell plasma membrane transport proteins Antigens Molecular Biology media_common therapy Cell plasma membrane Chemistry Cell Membrane Membrane Transport Proteins Single-Domain Antibodies Transmembrane protein nanobodies Cell biology Transport protein Cytosol 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis |
| Zdroj: | Biomolecules Biomolecules, Vol 11, Iss 63, p 63 (2021) |
| Popis: | Cell plasma membrane proteins are considered as gatekeepers of the cell and play a major role in regulating various processes. Transport proteins constitute a subclass of cell plasma membrane proteins enabling the exchange of molecules and ions between the extracellular environment and the cytosol. A plethora of human pathologies are associated with the altered expression or dysfunction of cell plasma membrane transport proteins, making them interesting therapeutic drug targets. However, the search for therapeutics is challenging, since many drug candidates targeting cell plasma membrane proteins fail in (pre)clinical testing due to inadequate selectivity, specificity, potency or stability. These latter characteristics are met by nanobodies, which potentially renders them eligible therapeutics targeting cell plasma membrane proteins. Therefore, a therapeutic nanobody-based strategy seems a valid approach to target and modulate the activity of cell plasma membrane transport proteins. This review paper focuses on methodologies to generate cell plasma membrane transport protein-targeting nanobodies, and the advantages and pitfalls while generating these small antibody-derivatives, and discusses several therapeutic nanobodies directed towards transmembrane proteins, including channels and pores, adenosine triphosphate-powered pumps and porters. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|